NO20071245L - Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. - Google Patents

Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.

Info

Publication number
NO20071245L
NO20071245L NO20071245A NO20071245A NO20071245L NO 20071245 L NO20071245 L NO 20071245L NO 20071245 A NO20071245 A NO 20071245A NO 20071245 A NO20071245 A NO 20071245A NO 20071245 L NO20071245 L NO 20071245L
Authority
NO
Norway
Prior art keywords
raf inhibitors
quinazolinone derivatives
marrow
chemical compounds
relates
Prior art date
Application number
NO20071245A
Other languages
English (en)
Inventor
Paul Dermot Lyne
Brian Aquila
Timothy Pontz
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20071245L publication Critical patent/NO20071245L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen angår kjemiske forbindelser med formel (I): eller farmasøytisk akseptable salter derav, som har B-Raf-hemmende aktivitet og følgelig er anvendelige for deres anti-kreft-aktivitet og således ved metoder for behandling av mermeske- eller dyrekroppen. Oppfirmelsen angår også fremgangsmåter for fremstilling av nevnte kjemiske forbindelser, farmasøytiske preparater irmeholdende dem og anvendelse av dem ved fremstilling av medikamenter anvendelige for produksjon av en anti-kreft-efifekt hos et varmblodig dyr så som mermesker.
NO20071245A 2004-09-01 2007-03-07 Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. NO20071245L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60653504P 2004-09-01 2004-09-01
PCT/GB2005/003336 WO2006024836A1 (en) 2004-09-01 2005-08-26 Quinazolinone derivatives and their use as b-raf inhibitors

Publications (1)

Publication Number Publication Date
NO20071245L true NO20071245L (no) 2007-05-24

Family

ID=35149373

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071245A NO20071245L (no) 2004-09-01 2007-03-07 Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.

Country Status (16)

Country Link
US (1) US20090054469A1 (no)
EP (1) EP1789400A1 (no)
JP (1) JP2008511600A (no)
KR (1) KR20070055575A (no)
CN (1) CN101010303A (no)
AR (1) AR050545A1 (no)
AU (1) AU2005278961A1 (no)
BR (1) BRPI0514679A (no)
CA (1) CA2577278A1 (no)
IL (1) IL181213A0 (no)
MX (1) MX2007002433A (no)
NO (1) NO20071245L (no)
TW (1) TW200621259A (no)
UY (1) UY29092A1 (no)
WO (1) WO2006024836A1 (no)
ZA (1) ZA200701366B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1957461B1 (en) * 2005-11-14 2016-11-02 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
WO2007113558A2 (en) * 2006-04-05 2007-10-11 Astrazeneca Ab Quinazolinone derivatives having b-raf inhibitory activity
JP2009534364A (ja) * 2006-04-18 2009-09-24 アストラゼネカ アクチボラグ キナゾリン−４−オン誘導体、それらの製造方法およびそれらを含有する医薬組成物
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US8669256B2 (en) 2010-05-28 2014-03-11 Merck Sharp & Dohme B.V. Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity
EP2580322B1 (en) 2010-06-09 2018-01-10 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
NZ711373A (en) * 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
JP6038212B2 (ja) * 2015-03-18 2016-12-07 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2444605A (en) * 1945-12-15 1948-07-06 Gen Aniline & Film Corp Stabilizers for photographic emulsions
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
BR9912729A (pt) * 1998-08-04 2001-05-02 Astrazeneca Ab Derivado de amida, processo para prepará-lo, e, uso do mesmo
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.

Also Published As

Publication number Publication date
AR050545A1 (es) 2006-11-01
IL181213A0 (en) 2007-07-04
CN101010303A (zh) 2007-08-01
MX2007002433A (es) 2007-05-04
US20090054469A1 (en) 2009-02-26
KR20070055575A (ko) 2007-05-30
BRPI0514679A (pt) 2008-06-17
ZA200701366B (en) 2008-09-25
UY29092A1 (es) 2006-04-28
CA2577278A1 (en) 2006-03-09
AU2005278961A1 (en) 2006-03-09
TW200621259A (en) 2006-07-01
JP2008511600A (ja) 2008-04-17
EP1789400A1 (en) 2007-05-30
WO2006024836A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20091683L (no) Kjemiske forbindelser
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20082709L (no) Kjemiske forbindelser
NO20073719L (no) Kjemiske forbindelser
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20071504L (no) Pyrimidinderivanter.
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
TW200635899A (en) Chemical compounds
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
NO20070566L (no) Azin-karboksamider som antikreftmiddel
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
NO20085218L (no) Nye pyridinanaloger
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20091703L (no) Heterocykliske sylfonamider med EDG-I antagonistisk aktivitet
AU2009282962A8 (en) Compounds as kinase inhibitors
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity